trial

Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects

NCTId NCT06787781
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 15 (actual)
Sponsored by University of Messina
Primary completion 2021-06-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
15 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-06-01
Primary completion
2021-06-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Alpha Lipoic Acid

Sponsors

University of MessinaLead Sponsor

Sites

1 total
Messina, Italy

Facts & assertions

4 sourced
Enrollment
15
Phase
NA
Primary Completion Date
2021-06-01
Status
COMPLETED
relationships
The graph out of here
drug
Alpha Lipoic Acid
drug
lead_sponsor
University of Messina
company
indication
Metabolic Evaluation
indication
Schizophrenia
indication
Cardiac Complications
indication